Targeted radiotherapy for malignant neuroendocrine tumors with I-131 metaiodobenzylguanidine (MIBG)
Not Applicable
- Conditions
- malignant neuroendocrine tumors
- Registration Number
- JPRN-UMIN000002529
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)pregnant female and feeding female 2)patients with disturbed consciousness 3)expected life interval less than 1 month 4)limited bone marrow capacity Hb<9.0, WBC count<3,000, platelet count <100,000 5)renal disorder GFR<30 ml/min/1.73 m2 6)risks for the central nerve system during treatment 7)in case that radiation safety cannot be secured. in case with uncontrolled symptoms that may require emergent medical cares. in case that understanding and cooperation cannot be obtained from family members. 8) when medical staff determine that treatment cannot be properly carried out.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)assessment of anti-tumor effects with tumor size and tumor markers 2)assessment of prognosis 3)assessment of symptoms
- Secondary Outcome Measures
Name Time Method